NeuroBo Pharmaceuticals announced the appointment of Marshall Woodworth as CFO, Principal Financial Officer and Principal Accounting Officer, effective March 1, following his tenure as Acting CFO since October 27, 2023. Prior to joining NeuroBo Pharmaceuticals, from May 2017 through May 2023, Woodworth served as the CFO at Nevakar.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on NRBO:
- NeuroBo Pharmaceuticals Announces Key Leadership Appointment
- NeuroBo Pharmaceuticals receives first site IRB approval for obesity trial
- NeuroBo Pharmaceuticals Signals Updates in Corporate Outlook
- NeuroBo’s DA-1726 Obesity Therapy Gets FDA IND Approval
- NeuroBo Pharmaceuticals: FDA clears IND application for DA-1726